Observational studyAIDS (London, England)2025
'With age comes wisdom': effectiveness and tolerability of dolutegravir + lamivudine in virologically-suppressed people with HIV.
Observational study in AIDS (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- 'Leaving no stones unturned': up to 10 years results on the effectiveness, tolerability and metabolic safety of dolutegravir+lamivudine (DTG+3TC) as a switch regimen in the ODOACRE cohort.The Journal of antimicrobial chemotherapy · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesResults from clinical trials and observational studies suggest that dolutegravir plus lamivudine is a well tolerated option for simplification in people with HIV (PWH). We aimed to assess long-time effectiveness and safety in our cohort.
methodsWe performed an observational study enrolling HIV-1-infected, virologically suppressed PWH, switching to dolutegravir plus lamivudine. Exclusion criteria were HBV-coinfection and the presence of the M184V mutation before the simplification. We performed survival analysis to evaluate time to virological failure (VF, defined by a single HIV-RNA ≥200 copies/ml or by two consecutive HIV-RNA ≥ 50 copies/ml) and treatment discontinuation (TD, defined as the interruption of either 3TC or DTG).
resultsSix hundred thirty-one PWH were considered for the analysis: 446 were males (70.7%), with a median age of 51.1 years [interquartile range (IQR) 42.6-57.6]. Estimated probabilities of maintaining virological suppression at 192 and 384 weeks were 95.1% [95% confidence interval (CI) 92.0-96.2] and 91.5% (95% CI 87.1-94.4), respectively. At multivariable analysis, including zenith HIV-RNA, time of virological suppression before switch, risk factors for HIV infection and age, only intravenous drug users (IDU) [versus other risk factors, adjusted hazard ratio (aHR) 3.58, 95% CI 1.38-9.28, P = 0.009] independently predicted VF. A border-line significant association with VF emerged for age (per 10-years more, aHR 0.72, 95% CI 0.51-1.01, P = 0.058) and zenith HIV-RNA >500 000 cps/ml (versus. <500 000 cps/ml, aHR 2.31, 95% CI 0.98-5.46, P = 0.056).As to treatment tolerability, estimated probabilities of remaining on study regimen at 192 and 384 weeks were 87.8% (95% CI 84.5-90.5) and 85.1% (95% CI 81.0-88.5), respectively.
conclusionsOur findings confirm the long-term effectiveness and tolerability of dolutegravir plus lamivudine in virologically suppressed PWH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.